gdc
Multiple MyelomaSlideshows

Multiple Myeloma

March is multiple myeloma month. Check out our slideshow on this cancer type.
Web Exclusives – March 28, 2017

  • Centers For Disease Control Co 768x512

    March is Multiple Myeloma Awareness Month. Here are some risk factors and statistics related to the disease.

  • Diverse Group 768x512

    In 2017, an estimated 30,280 new cases of multiple myeloma will be diagnosed, including 17,490 men and 12,790 women.

    Source: The American Cancer Society
  • Senior Couple On Bicycles 768x512

    Multiple myeloma is more than twice as common in African Americans as in white Americans.

    Source: The American Cancer Society
  • Mother Grown Son 768x512

    People who have a sibling or parent with multiple myeloma are 4 times more likely to have the disease.

    Source: The American Cancer Society
  • Mm Cells 768x512

    This disease is the second most common blood cancer in the world.

    Source: International Myeloma Foundation
  • Cq Logo

    To read more about multiple myeloma, check out our articles here.  

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Multiple Myeloma
CAR T-Cell Therapies Produce Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
By Chase Doyle
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
Multiple Myeloma
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma
By Chase Doyle
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Blenrep for Patients with Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Last modified: October 3, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country